Scaffold Hopping with Molecular Field Points: Identification of a Cholecystokinin-2 (CCK2) Receptor Pharmacophore and Its Use in the Design of a Prototypical Series of Pyrrole- and Imidazole-Based CCK2 Antagonists
- 11 October 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (22) , 6790-6802
- https://doi.org/10.1021/jm049069y
Abstract
A new molecular modeling approach has been used to derive a pharmacophore of the potent and selective cholecystokinin-2 (CCK2) receptor antagonist 5 (JB93182), based on features shared with two related series. The technique uses “field points” as simple and effective descriptions of the electrostatic and van der Waals maxima and minima surrounding a molecule equipped with XED (extended electron distribution) charges. Problems associated with the high levels of biliary elimination of 5 in vivo required us to design a compound with significantly lower molecular weight without sacrificing its nanomolar levels of in vitro activity. Two new series of compounds were designed to mimic the arrangement of field points present in the pharmacophore rather than its structural elements. In a formal sense, two of the three amides in 5 were replaced with either a simple pyrrole or imidazole, while some features thought to be essential for the high levels of in vitro activity of the parent compounds were retained and others deleted. These compounds maintained activity and selectivity for this receptor over CCK1. In addition, the reduction in molecular weight coupled with lower polarities greatly reduced levels of biliary elimination associated with 5. This makes them good lead compounds for development of drug candidates whose structures are not obviously related to those of the parents and represents the first example of scaffold hopping using molecular field points.Keywords
This publication has 32 references indexed in Scilit:
- CCK2receptor antagonistsExpert Opinion on Therapeutic Patents, 2001
- A comparison of conformational energies calculated by several molecular mechanics methodsJournal of Computational Chemistry, 1996
- Non-Peptide Cholecystokinin-B/Gastrin Receptor Antagonists Based on Bicyclic, Heteroaromatic SkeletonsJournal of Medicinal Chemistry, 1996
- Improving the Affinity and Selectivity of a Nonpeptide Series of Cholecystokinin-B/Gastrin Receptor Antagonists Based on the Dibenzobicyclo[2.2.2]octane SkeletonJournal of Medicinal Chemistry, 1995
- A New Class of Non-peptidic Cholecystokinin-B/Gastrin Receptor Antagonists Based on Dibenzobicyclo[2.2.2]octaneJournal of Medicinal Chemistry, 1994
- Molecular Cloning and Functional Expression of the Human Gallbladder Cholecystokinin A ReceptorBiochemical and Biophysical Research Communications, 1993
- Synthesis and Antiallergy Activity of (1,3,4)Thiadiazolo(3,2-a)-1,2,3-triazolo(4,5-d)pyrimidin-9(3H)-one Derivatives. II. 6-Alkyl- and 6-Cycloalkylalkyl Derivatives.CHEMICAL & PHARMACEUTICAL BULLETIN, 1992
- Preparation, characterization, and anticancer activity of a series of cis-PtCl2 complexes linked to anthraquinone intercalatorsJournal of Medicinal Chemistry, 1991
- The nature of .pi.-.pi. interactionsJournal of the American Chemical Society, 1990
- Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugarsJournal of Medicinal Chemistry, 1989